Merck (#MRK) and Moderna (#MRNA) reported positive results from a Phase 3 trial of their personalized mRNA cancer vaccine, which slowed melanoma recurrence and reduced the spread of the disease to other parts of the body. The study was stopped at its first interim analysis after meeting the criteria for positive results, although the magnitude of the benefit has not yet been disclosed. Sector: Biotechnology / Pharmaceuticals Key Highlights 🧬 Personalized mRNA cancer vaccine 🩺 Phase 3 melanoma trial delivered positive results 📉 Slowed melanoma recurrence and disease spread ✅ Trial stopped at the first interim analysis 🔬 Full magnitude of benefit remains undisclosed 🤝 Merck and Moderna partnership advances mRNA oncology 🚀 Potentially significant development for cancer treatment Why It Matters Positive Phase 3 results could represent a major milestone for personalized mRNA cancer vaccines and strengthen the potential of mRNA technology as a platform for treating cancer. Read More: https://www.thinksabio.com/reports/isr/MRNA